Skip to main content
. 2019 Jul 11;18(6):1460–1466. doi: 10.5114/aoms.2019.86569

Table III.

Characteristics of 4 non-responders to 12-week LDV/SOF±RBV regimens

Patient Regimen Genotype History of previous therapy Fibrosis Baseline HCV RNA × 106 IU/ml EOT Comment
Male 1 LDV/SOF 1B Treatment-naïve 3 2.87 TND Advanced fibrosis
Male 2 LDV/SOF 1B Treatment-naïve 3 0.62 TD Advanced fibrosis
Female 1 LDV/SOF 1B Treatment-naïve 2 0.20 TND None
Female 2 LDV/SOF 1B Treatment-naïve 2 0.46 TND None

LDV – ledipasvir, SOF – sofosbuvir, HCV RNA – hepatitis C virus ribonucleic acid, EOT – end of treatment, TND – target not detected, TD – target detected.